The 2026 GLP-1 Telehealth Enforcement Wave, Explained

If you get compounded GLP-1 medication through a telehealth company, or you are thinking about it, 2026 has been a year worth paying attention to. Federal regulators have moved against some of the largest names in the category, and the pattern in those actions says a lot about what patients should be checking before they hand any provider their health history and a credit card.

Here is what has actually happened, based on the public record, and what it means practically. A note before the list: these are allegations and regulatory actions, not court verdicts. The allegations described below have not been proven in court, and the companies involved are entitled to contest them.

The timeline

July 29, 2026. The Federal Trade Commission, joined by the State of Utah and Los Angeles County, filed a federal complaint against Hims & Hers Health, one of the largest telehealth companies in the country. The complaint alleges two things. First, that the company shared customers’ sensitive health information, including medical conditions, with third-party advertising platforms such as Meta and Snap, despite marketing its services as private. Second, that it engaged in deceptive subscription billing and cancellation practices, including charging customers without adequate consent and making cancellation difficult. Hims & Hers also faces a separately reported SEC inquiry into its disclosures around compounded GLP-1 products, and a private class action alleging that its compounded semaglutide was advertised as equivalent to the brand-name semaglutide medications. Earlier in the year, the manufacturer of those brand-name medications sued the company over its compounded semaglutide sales, a suit that was later dropped.

April 2026. The FTC and the Department of Justice moved against Zealthy, a GLP-1 telehealth company led by the founding CEO of Cerebral, seeking to place the company under court supervision. The government’s filings allege continued deceptive practices around disclosures, cancellation, and review manipulation, along with a more serious claim: that prescriptions were issued using medical providers’ National Provider Identifier numbers without those providers’ knowledge or consent.

February through June 2026. The FDA sent warning letters to more than 30 telehealth companies marketing compounded GLP-1 medications, followed by another batch of 25 in June. The letters largely targeted marketing claims: compounded products promoted as if they were the FDA-approved brand-name drugs, safety claims without adequate substantiation, and results promises the companies could not support.

December 2025. The FTC finalized its order against NextMed, a telemedicine firm it charged with using misleading prices, fake reviews, and deceptive weight-loss claims to sell GLP-1 programs.

The pattern

Read together, the actions cluster around three failure modes, and none of them is about the medicine itself.

The billing trap. Regulators keep finding the same structure: an advertised price that is not the real price, a subscription that is easy to start and hard to stop, and charges that continue past the point the customer understood. The FTC’s Hims & Hers complaint and the NextMed order both center on it.

The data trade. Health information flowing to advertising platforms while the marketing promises privacy. This is the newest front, and the one most invisible to patients, because nothing about the checkout experience tells you where your intake answers go afterward.

The marketing shortcut. Compounded medication presented as interchangeable with brand-name drugs, or sold with outcome promises no one can substantiate. This is what most of the FDA’s 55-plus warning letters this year were about.

What this means if you are choosing a provider

The useful response to an enforcement wave is not fear of the category. Compounded GLP-1 therapy through telehealth is legal, and for many people it is the only affordable path to treatment. The useful response is a short checklist, applied to every provider, including us:

1. Get the whole bill in writing before you pay. The all-in monthly number, at your dose, after any intro period, with every fee included. If a provider cannot put that on one line, the enforcement record shows you why. We published a full comparison of what GLP-1 programs actually cost on exactly this principle.
2. Read the cancellation terms before the price. Month-to-month means you can stop. Contract language about remaining balances means you cannot, not cheaply.
3. Verify the prescriber exists and is licensed in your state. Every state medical board runs a free public lookup. The Zealthy allegations, involving prescriptions issued under providers’ names without their consent, are the reason this check earns two minutes of your time.
4. Ask which pharmacy fills the prescription. A licensed 503A compounding pharmacy or 503B outsourcing facility, named before you commit.
5. Read the privacy policy for the words “advertising” and “third parties.” The July complaint is a reminder that where your health information travels is a term of the deal, whether or not it is presented as one.

We examined the highest-profile case of this kind separately: the Hims & Hers lawsuit as a test of telehealth trust.

Where we stand

Gentle Health operates in this category, so it is fair to ask how we hold up against that checklist, and fair for us to answer only with things you can verify.

Our billing is the simplest structure we know how to offer: oral semaglutide starts at $112 per month, injectable semaglutide starts at $135 per month, and tirzepatide starts at $169 per month, with the monthly price based on the prescribed dose tier, no membership fee, and no contract balance if you stop. Cancellation is part of that structure rather than an exception to it: under our terms, you can cancel an order and the subscription any time before the order is sent to the pharmacy, and the subscription 30 days after the order date once it has been sent, effective immediately. The remainder of the current billing month is not refunded. That structure was a deliberate choice, and the enforcement record this year is a good explanation of why we made it. The prescriber is not a network or a panel: every prescription in every state we serve is written by James Simmons, MD, licensed in every state we serve, from Arkansas (license E-14098) and Kentucky (license 59884) onward, and each of our state pages links to that state’s medical board verification record so you can check rather than trust.

We would rather be the provider whose practices make that checklist boring. Integrity in this category is not a slogan; it is a pricing page that does the arithmetic for you and a license number you can look up.

Sources

• FTC press release and complaint, FTC v. Hims & Hers Health, filed July 29, 2026 (ftc.gov); coverage: Forbes, July 29, 2026; Fierce Healthcare, July 2026
• FTC and DOJ action regarding Zealthy, April 2026; coverage: Behavioral Health Business, April 20, 2026
• FTC final order against NextMed, December 2025 (ftc.gov)
• FDA warning letters to telehealth companies marketing compounded GLP-1 medications, February-June 2026 (fda.gov); coverage: Reuters, June 16, 2026
• Frier Levitt client alerts on the FTC action and FDA warning letters, 2026

Current Gentle Health dose tiers and pricing

Gentle Health pricing depends on the dose tier prescribed by your clinician. Current monthly prices are:

Oral compounded semaglutide

Injectable compounded semaglutide

Injectable compounded tirzepatide

Medication, the initial review by a licensed clinician, video visits and messaging, and overnight refrigerated shipping are included. There is no separate membership fee, and HSA and FSA cards are accepted. Your clinician determines the appropriate medication and dose; the monthly price changes if the prescribed dose moves into a different tier.

Dr. James Simmons, MD